Incretin Physiology and Pharmacology in the Intensive Care Unit

Mark P Plummer; Jeroen Hermanides; Adam M Deane

doi:https://doi.org/10.1016/j.ccc.2018.11.011

Incretin Physiology and Pharmacology in the Intensive Care Unit

Mark P Plummer, Jeroen Hermanides, Adam M Deane

Research output: Contribution to journal › Review article › Academic › peer-review

5 Citations (Scopus)

Abstract

In health, postprandial glycemic excursions are attenuated via stimulation of insulin secretion, suppression of glucagon secretion, and slowing of gastric emptying. The incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are primary modulators of this response. Drugs have recently been developed that exploit the incretin-axis for the management of type 2 diabetes. There is burgeoning interest in the potential of incretin therapies for the management of acute hyperglycemia in the critically ill. This article outlines basic incretin physiology, highlights relevant pharmacology, and briefly summarizes the literature on incretins for glycemic control in the critically ill.

Original language	English
Pages (from-to)	341-355
Number of pages	15
Journal	Critical Care Clinics
Volume	35
Issue number	2
DOIs	https://doi.org/10.1016/j.ccc.2018.11.011
Publication status	Published - Apr 2019

Keywords

Adult
Aged
Aged, 80 and over
Blood Glucose/drug effects
Critical Care/methods
Diabetes Mellitus, Type 2/drug therapy
Female
Gastric Inhibitory Polypeptide/therapeutic use
Glucagon-Like Peptide 1/therapeutic use
Glycemic Index/drug effects
Humans
Hypoglycemic Agents/therapeutic use
Incretins/therapeutic use
Male
Middle Aged
Receptors, Gastrointestinal Hormone/therapeutic use

Access to Document

https://doi.org/10.1016/j.ccc.2018.11.011

Cite this

@article{cb836761bdab4285814c239a0c9e52fc,

title = "Incretin Physiology and Pharmacology in the Intensive Care Unit",

abstract = "In health, postprandial glycemic excursions are attenuated via stimulation of insulin secretion, suppression of glucagon secretion, and slowing of gastric emptying. The incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are primary modulators of this response. Drugs have recently been developed that exploit the incretin-axis for the management of type 2 diabetes. There is burgeoning interest in the potential of incretin therapies for the management of acute hyperglycemia in the critically ill. This article outlines basic incretin physiology, highlights relevant pharmacology, and briefly summarizes the literature on incretins for glycemic control in the critically ill.",

keywords = "Adult, Aged, Aged, 80 and over, Blood Glucose/drug effects, Critical Care/methods, Diabetes Mellitus, Type 2/drug therapy, Female, Gastric Inhibitory Polypeptide/therapeutic use, Glucagon-Like Peptide 1/therapeutic use, Glycemic Index/drug effects, Humans, Hypoglycemic Agents/therapeutic use, Incretins/therapeutic use, Male, Middle Aged, Receptors, Gastrointestinal Hormone/therapeutic use",

author = "Plummer, {Mark P} and Jeroen Hermanides and Deane, {Adam M}",

year = "2019",

month = apr,

doi = "https://doi.org/10.1016/j.ccc.2018.11.011",

language = "English",

volume = "35",

pages = "341--355",

journal = "Critical Care Clinics",

issn = "0749-0704",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Incretin Physiology and Pharmacology in the Intensive Care Unit

AU - Plummer, Mark P

AU - Hermanides, Jeroen

AU - Deane, Adam M

PY - 2019/4

Y1 - 2019/4

N2 - In health, postprandial glycemic excursions are attenuated via stimulation of insulin secretion, suppression of glucagon secretion, and slowing of gastric emptying. The incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are primary modulators of this response. Drugs have recently been developed that exploit the incretin-axis for the management of type 2 diabetes. There is burgeoning interest in the potential of incretin therapies for the management of acute hyperglycemia in the critically ill. This article outlines basic incretin physiology, highlights relevant pharmacology, and briefly summarizes the literature on incretins for glycemic control in the critically ill.

AB - In health, postprandial glycemic excursions are attenuated via stimulation of insulin secretion, suppression of glucagon secretion, and slowing of gastric emptying. The incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are primary modulators of this response. Drugs have recently been developed that exploit the incretin-axis for the management of type 2 diabetes. There is burgeoning interest in the potential of incretin therapies for the management of acute hyperglycemia in the critically ill. This article outlines basic incretin physiology, highlights relevant pharmacology, and briefly summarizes the literature on incretins for glycemic control in the critically ill.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Blood Glucose/drug effects

KW - Critical Care/methods

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Female

KW - Gastric Inhibitory Polypeptide/therapeutic use

KW - Glucagon-Like Peptide 1/therapeutic use

KW - Glycemic Index/drug effects

KW - Humans

KW - Hypoglycemic Agents/therapeutic use

KW - Incretins/therapeutic use

KW - Male

KW - Middle Aged

KW - Receptors, Gastrointestinal Hormone/therapeutic use

U2 - https://doi.org/10.1016/j.ccc.2018.11.011

DO - https://doi.org/10.1016/j.ccc.2018.11.011

M3 - Review article

C2 - 30784614

SN - 0749-0704

VL - 35

SP - 341

EP - 355

JO - Critical Care Clinics

JF - Critical Care Clinics

IS - 2

ER -